S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Vaxart Stock Forecast, Price & News

+0.18 (+2.59 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $7.14
50-Day Range
MA: $6.94
52-Week Range
Now: $7.14
Volume5.04 million shs
Average Volume5.75 million shs
Market Capitalization$781.61 million
P/E RatioN/A
Dividend YieldN/A
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. Vaxart, Inc. is headquartered in South San Francisco, California.
Vaxart logo


Overall MarketRank

1.33 out of 5 stars

Medical Sector

658th out of 1,923 stocks

Biological Products, Except Diagnostic Industry

87th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:VXRT
Previous SymbolNASDAQ:NABI
Phone(650) 550-3500



Sales & Book Value

Annual Sales$9.86 million
Book Value$0.27 per share


Net Income$-18,650,000.00
Net Margins-281.50%


Market Cap$781.61 million
Next Earnings Date3/18/2021 (Estimated)
OptionableNot Optionable
+0.18 (+2.59 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Vaxart (NASDAQ:VXRT) Frequently Asked Questions

How has Vaxart's stock been impacted by COVID-19 (Coronavirus)?

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VXRT shares have increased by 244.9% and is now trading at $7.14.
View which stocks have been most impacted by COVID-19

Is Vaxart a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vaxart stock.
View analyst ratings for Vaxart
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Vaxart?

Wall Street analysts have given Vaxart a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vaxart wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Vaxart's next earnings date?

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Vaxart

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) announced its quarterly earnings data on Thursday, November, 12th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The biotechnology company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $1.60 million. Vaxart had a negative net margin of 281.50% and a negative trailing twelve-month return on equity of 84.90%.
View Vaxart's earnings history

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart's stock reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for VXRT?

2 brokers have issued 12 month price targets for Vaxart's shares. Their forecasts range from $17.00 to $22.00. On average, they expect Vaxart's stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 173.1% from the stock's current price.
View analysts' price targets for Vaxart
or view Wall Street analyst' top-rated stocks.

Who are some of Vaxart's key competitors?

What other stocks do shareholders of Vaxart own?

Who are Vaxart's key executives?

Vaxart's management team includes the following people:
  • Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 52, Pay $353.37k)
  • Ms. Margaret A. Echerd, VP, Corp. Controller & Principal Accounting Officer (Age 61, Pay $290.18k)
  • Mr. Cezar Andrei Floroiu M.B.A., CEO, Pres, Principal Financial Officer & Director (Age 47)
  • Ms. Shaily Jaini Garg, Sr. VP of Clinical Devel. & Project Management
  • Mr. Brant Biehn, Sr. VP of Commercial Operations
  • Dr. Richard M. Schwartz, Sr. VP of Technical Operations
  • Mr. John M. Harland M.B.A., CPA, Consultant (Age 68)

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a variety of institutional and retail investors. Top institutional investors include Strategic Wealth Management Group LLC (0.09%) and Pacer Advisors Inc. (0.02%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart

Which institutional investors are selling Vaxart stock?

VXRT stock was sold by a variety of institutional investors in the last quarter, including Strategic Wealth Management Group LLC. Company insiders that have sold Vaxart company stock in the last year include Armistice Capital, Llc, Todd C Davis, and Wouter Latour.
View insider buying and selling activity for Vaxart
or view top insider-selling stocks.

Which institutional investors are buying Vaxart stock?

VXRT stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart
or or view top insider-buying stocks.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $7.14.

How big of a company is Vaxart?

Vaxart has a market capitalization of $781.61 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 30 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is www.vaxart.com.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at (650) 550-3500 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.